Summary
Signal counts
Assets tracked: 3
Watchlist assets: 2
Registry stop assets: 1
Sponsor overview
GlaxoSmithKline
Public clinical-program risk signals across linked oncology Phase 2 assets for this sponsor.
Evidence links
Public sources
https://clinicaltrials.gov/study/NCT02314143 | https://clinicaltrials.gov/study/NCT00422903 | https://clinicaltrials.gov/study/NCT05714839
Assets
Linked programs
- Dabrafenib: Registry Stop Signal (4/5)
- lapatinib: Low Signal (0/5)
- Unconjugated belantamab antibody: Operational Burden Signal (2/5)